Skip to main content
. Author manuscript; available in PMC: 2019 Apr 23.
Published in final edited form as: Prog Neurobiol. 2015 Jun 11;131:21–64. doi: 10.1016/j.pneurobio.2015.05.002

Table 5.

Epigenetic dysregulation in Parkinson’s disease: DNA (de)methylation.

Gene Regulation Epigenetic modification Observed in Sample size Approach Methods Reference
SNCA ↓ Methylation sPD patients (SN,
Putamen, Cortex)		 6, 14 Targeted
(1 locus)		 BS Jowaed et al., 2010
11 Targeted
(1 locus)		 BS Matsumoto et al., 2010
PARK16 ≠ Methylation PD patients 12.386 Genome-wide methQTL Plagnol et al., 2011
GPNMB ≠ Methylation PD patients
STX1B ≠ Methylation PD patients
FANCC ≠ Methylation PD patients 30 Genome-wide Infinium Moore et al., 2014
TNKS2
↓

indicates decreased expression levels and

≠

indicates altered expression, not further specified.

Abbreviations: FANCC, fanconi anemia group C; GPNMB, glycoprotein (transmembrane) nmb; PARK16, Parkinson disease 16; (s)PD, (sporadic) Parkinson’s disease; SN, substantia nigra; SNCA, synuclein alpha; sPD, sporadic PD; STX1B, syntaxin 1B; TNKS2, tankyrase 2; BS, bisulfite sequencing; GWA: genome-wide association; methQTL, methylation quantitative trait locusc.